Trials / Completed
CompletedNCT02545465
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
Retrospective Chart Review of Patients With PAH or Inoperable/Persistent/Recurrent CTEPH Who Transition Their PH Treatment to Adempas
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 125 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice. In addition, this study will describe patient demographics and reason for switching
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Riociguat (Adempas, BAY63-2521) | As per the treating physicians discretion |
Timeline
- Start date
- 2015-09-15
- Primary completion
- 2016-05-31
- Completion
- 2016-08-31
- First posted
- 2015-09-10
- Last updated
- 2017-05-24
Locations
7 sites across 7 countries: Belgium, Canada, Colombia, Germany, Japan, Sweden, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT02545465. Inclusion in this directory is not an endorsement.